{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:23:57Z","timestamp":1761895437777},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2012,2,13]],"date-time":"2012-02-13T00:00:00Z","timestamp":1329091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2012,2,13]],"date-time":"2012-02-13T00:00:00Z","timestamp":1329091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1038\/bmt.2012.1","type":"journal-article","created":{"date-parts":[[2012,2,13]],"date-time":"2012-02-13T12:27:19Z","timestamp":1329136039000},"page":"1312-1317","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Allo-SCT for multiple myeloma: a review of outcomes at a single transplant center"],"prefix":"10.1038","volume":"47","author":[{"given":"W","family":"Bensinger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Rotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Storer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Chauncey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Holmberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B M","family":"Sandmaier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Storb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Maloney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,2,13]]},"reference":[{"key":"BFbmt20121_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1053\/j.seminhematol.2003.09.010","volume":"40","author":"KC Anderson","year":"2003","unstructured":"Anderson KC . The role of immunomodulatory drugs in multiple myeloma (Review). Semin Hematol 2003; 40: 23\u201332.","journal-title":"Semin Hematol"},{"key":"BFbmt20121_CR2","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa043445","volume":"352","author":"PG Richardson","year":"2005","unstructured":"Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487\u20132498.","journal-title":"N Engl J Med"},{"issue":"Part 1","key":"BFbmt20121_CR3","first-page":"239a","volume":"108","author":"M Lacy","year":"2006","unstructured":"Lacy M, Gertz M, Dispenzieri A, Hayman S, Geyer S, Zeldenrust S et al. Lenalidomide plus dexamethasone (Rev\/Dex) in newly diagnosed myeloma: response to therapy, time to progression, and survival. Blood 2006; 108 (Part 1): 239a, #798.","journal-title":"Blood"},{"key":"BFbmt20121_CR4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1056\/NEJM199607113350204","volume":"335","author":"M Attal","year":"1996","unstructured":"Attal M, Harousseau J-L, Stoppa A-M, Sotto J-J, Fuzibet J-G, Rossi J-F et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335: 91\u201397.","journal-title":"N Engl J Med"},{"key":"BFbmt20121_CR5","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1056\/NEJMoa022340","volume":"348","author":"JA Child","year":"2003","unstructured":"Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875\u20131883.","journal-title":"N Engl J Med"},{"key":"BFbmt20121_CR6","doi-asserted-by":"publisher","first-page":"9227","DOI":"10.1200\/JCO.2005.03.0551","volume":"23","author":"JP Fermand","year":"2005","unstructured":"Fermand JP, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 2005; 23: 9227\u20139233.","journal-title":"J Clin Oncol"},{"key":"BFbmt20121_CR7","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1182\/blood-2007-08-104984","volume":"111","author":"H Brenner","year":"2008","unstructured":"Brenner H, Gondos A, Pulte D . Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008; 111: 2521\u20132526.","journal-title":"Blood"},{"key":"BFbmt20121_CR8","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1182\/blood.V87.3.1196.bloodjournal8731196","volume":"87","author":"G Tricot","year":"1996","unstructured":"Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B . Graft-versus-myeloma effect: proof of principle. Blood 1996; 87: 1196\u20131198.","journal-title":"Blood"},{"key":"BFbmt20121_CR9","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1200\/JCO.1999.17.1.208","volume":"17","author":"P Corradini","year":"1999","unstructured":"Corradini P, Voena C, Tarella C, Astolfi M, Ladetto M, Palumbo A et al. Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. J Clin Oncol 1999; 17: 208\u2013215.","journal-title":"J Clin Oncol"},{"key":"BFbmt20121_CR10","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.exphem.2009.03.008","volume":"37","author":"N Kroger","year":"2009","unstructured":"Kroger N, Badbaran A, Lioznov M, Schwarz S, Zeschke S, Hildebrand Y et al. Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma. Exp Hematol 2009; 37: 791\u2013798.","journal-title":"Exp Hematol"},{"key":"BFbmt20121_CR11","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1182\/blood.V88.7.2787.bloodjournal8872787","volume":"88","author":"WI Bensinger","year":"1996","unstructured":"Bensinger WI, Buckner CD, Anasetti C, Clift R, Storb R, Barnett T et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 1996; 88: 2787\u20132793.","journal-title":"Blood"},{"key":"BFbmt20121_CR12","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1046\/j.1365-2141.2001.02726.x","volume":"113","author":"G Gahrton","year":"2001","unstructured":"Gahrton G, Svensson H, Cavo M, Apperley J, Bacigalupo A, Bj\u00f6rkstand B et al. Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983\u201393 and 1994\u201398 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 2001; 113: 209\u2013216.","journal-title":"Br J Haematol"},{"key":"BFbmt20121_CR13","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1200\/JCO.1995.13.6.1291","volume":"13","author":"KC Anderson","year":"1995","unstructured":"Anderson KC . Who benefits from high-dose therapy for multiple myeloma? (editorial; comment). J Clin Oncol 1995; 13: 1291\u20131296.","journal-title":"J Clin Oncol"},{"key":"BFbmt20121_CR14","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1182\/blood-2002-09-2955","volume":"102","author":"DG Maloney","year":"2003","unstructured":"Maloney DG, Molina AJ, Sahebi F, Stockerl-Goldstein KE, Sandmaier BM, Bensinger W et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003; 102: 3447\u20133454.","journal-title":"Blood"},{"key":"BFbmt20121_CR15","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1046\/j.1365-2141.2003.04299.x","volume":"121","author":"H Einsele","year":"2003","unstructured":"Einsele H, Schafer HJ, Hebart H, Bader P, Meisner C, Plasswilm L et al. Follow-up of patients with progressive multiple myeloma undergoing allografts after reduced-intensity conditioning. Br J Haematol 2003; 121: 411\u2013418.","journal-title":"Br J Haematol"},{"key":"BFbmt20121_CR16","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1056\/NEJMoa065464","volume":"356","author":"B Bruno","year":"2007","unstructured":"Bruno B, Rotta M, Patriarca F, Mordini N, Allione B, Carnevale-Schianca F et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 2007; 356: 1110\u20131120.","journal-title":"N Engl J Med"},{"key":"BFbmt20121_CR17","doi-asserted-by":"publisher","first-page":"3474","DOI":"10.1182\/blood-2005-09-3869","volume":"107","author":"F Garban","year":"2006","unstructured":"Garban F, Attal M, Michallet M, Hulin C, Bourhis JH, Yakoub-Agha I et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 2006; 107: 3474\u20133480.","journal-title":"Blood"},{"key":"BFbmt20121_CR18","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1182\/blood-2008-02-141598","volume":"112","author":"L Rosi\u00f1ol","year":"2008","unstructured":"Rosi\u00f1ol L, P\u00e9rez-Sim\u00f3n JA, Sureda A, de la Rubia J, de Arriba F, Lahuerta JJ et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood 2008; 112: 3591\u20133593.","journal-title":"Blood"},{"key":"BFbmt20121_CR19","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1200\/JCO.2010.32.7312","volume":"29","author":"B Bjorkstrand","year":"2011","unstructured":"Bjorkstrand B, Iacobelli S, Hegenbart U, Gruber A, Greinix H, Volin L et al. Tandem autologous\/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. J Clin Oncol 2011; 29: 3016\u20133022.","journal-title":"J Clin Oncol"},{"key":"BFbmt20121_CR20","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1182\/blood.V116.21.24.24","volume":"116","author":"A Krishnan","year":"2010","unstructured":"Krishnan A, Pasquini MC, Ewell M, Stadtmauer EA, Alyea III EP, Antin JH et al. Tandem autologous hematopoietic stem cell transplants (AuHCT) with or without maintenance therapy (auto-auto) versus single AuHCT followed by HLA matched sibling non- myeloablative allogeneic HCT (auto-allo) for patients with standard risk (SR) multiple myeloma (MM); results from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0102 trial. Blood 2010; 116: 24\u201325, #41.","journal-title":"Blood"},{"key":"BFbmt20121_CR21","doi-asserted-by":"publisher","first-page":"3588","DOI":"10.1182\/blood-2006-07-036848","volume":"109","author":"C Crawley","year":"2007","unstructured":"Crawley C, Iacobelli S, Bj\u00f6rkstrand B, Apperley JF, Niederwieser D, Gahrton G . Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood 2007; 109: 3588\u20133594.","journal-title":"Blood"},{"key":"BFbmt20121_CR22","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","volume":"36","author":"BGM Durie","year":"1975","unstructured":"Durie BGM, Salmon SE . A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36: 842\u2013854.","journal-title":"Cancer"},{"key":"BFbmt20121_CR23","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BG Durie","year":"2006","unstructured":"Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K et al. International uniform response criteria for multiple myeloma [Erratum appears in Leukemia. 2007 May;21(5):1134] [Erratum appears in Leukemia. 2006 Dec;20(12):2220]. Leukemia 2006; 20: 1467\u20131473.","journal-title":"Leukemia"},{"key":"BFbmt20121_CR24","doi-asserted-by":"publisher","first-page":"4715","DOI":"10.1002\/cncr.24531","volume":"115","author":"A Gratwohl","year":"2009","unstructured":"Gratwohl A, Stern M, Brand R, Apperley J, Baldomero H, de Witte T et al. Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer 2009; 115: 4715\u20134726.","journal-title":"Cancer"},{"key":"BFbmt20121_CR25","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.3324\/haematol.11353","volume":"92","author":"G Gahrton","year":"2007","unstructured":"Gahrton G, Iacobelli S, Bandini G, Bjorkstrand B, Corradini P, Crawley C et al. Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma. Haematologica 2007; 92: 1513\u20131518.","journal-title":"Haematologica"},{"key":"BFbmt20121_CR26","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1182\/blood-2002-01-0131","volume":"100","author":"N Kroger","year":"2002","unstructured":"Kroger N, Schwerdtfeger R, Kiehl M, Sayer HG, Renges H, Zabelina T et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 2002; 100: 755\u2013760.","journal-title":"Blood"},{"key":"BFbmt20121_CR27","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.bbmt.2004.06.002","volume":"10","author":"N Kr\u00f6ger","year":"2004","unstructured":"Kr\u00f6ger N, Perez-Simon JA, Myint H, Klingemann H, Shimoni A, Nagler A et al. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan\/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant 2004; 10: 698\u2013708.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt20121_CR28","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1038\/leu.2008.88","volume":"22","author":"G Schilling","year":"2008","unstructured":"Schilling G, Hansen T, Shimoni A, Zabelina T, Simon-Perez JA, Gutierrez NC et al. Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma. Leukemia 2008; 22: 1250\u20131255.","journal-title":"Leukemia"},{"key":"BFbmt20121_CR29","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.bbmt.2010.07.003","volume":"17","author":"E Klyuchnikov","year":"2010","unstructured":"Klyuchnikov E, Sputtek A, Slesarchuk O, Lioznov M, St\u00fcbig T, Bacher U et al. Purification of CD4(+) T cells for adoptive immunotherapy after allogeneic hematopoeitic stem cell transplantation. Biol Blood Marrow Transplant 2010; 17: 374\u2013383.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt20121_CR30","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.bbmt.2010.02.018","volume":"16","author":"DA Rizzieri","year":"2010","unstructured":"Rizzieri DA, Storms R, Chen DF, Long G, Yang Y, Nikcevich DA et al. Natural killer cell-enriched donor lymphocyte infusions from A 3-6\/6 HLA matched family member following nonmyeloablative allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2010; 16: 1107\u20131114.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt20121_CR31","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/j.1365-2141.2008.07340.x","volume":"143","author":"J Shi","year":"2008","unstructured":"Shi J, Tricot G, Szmania S, Rosen N, Garg TK, Malaviarachchi PA et al. Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Br J Haematol 2008; 143: 641\u2013653.","journal-title":"Br J Haematol"},{"key":"BFbmt20121_CR32","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1182\/blood.V114.22.529.529","volume":"114","author":"M Attal","year":"2009","unstructured":"Attal M, Harousseau JL, Marit G, Caillot D, Stoppa AM, Benboubker L et al. Lenalidomide after autologous transplantation for myeloma: first analysis of a prospective, randomized study of the Intergroupe Francophone Du Myelome (IFM 2005 02). Blood 2009; 114: 220\u2013221.","journal-title":"Blood"},{"key":"BFbmt20121_CR33","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1182\/blood.V114.22.3416.3416","volume":"114","author":"PL McCarthy","year":"2009","unstructured":"McCarthy PL, Owzar K, Stadtmauer EA, Giralt S, Hurd DD, Hassoun H et al. Phase III intergroup study of lenalidomide (CC-5013) versus placebo maintenance therapy following single autologous stem cell transplant for multiple myeloma (CALBG 100104): initial reprot of patient accrual and adverse events. Blood 2009; 114: 1327.","journal-title":"Blood"},{"key":"BFbmt20121_CR34","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1182\/blood.V114.22.1491.1491","volume":"114","author":"AJ Jakubowiak","year":"2009","unstructured":"Jakubowiak AJ, Bensinger W, Siegel D, Zimmerman TM, Van Tornout JM, Zhao C et al. Phase 1\/2 study of elotuzumab in combination with bortezomib in patients with multiple myeloma with one to three prior therapies: interim results. Blood 2009; 114: 1491\u20131492.","journal-title":"Blood"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt20121.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt20121","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt20121.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T15:09:02Z","timestamp":1648048142000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt20121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,13]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["BFbmt20121"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2012.1","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,13]]},"assertion":[{"value":"6 May 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2011","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2011","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2012","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}